Capricor Therapeutics, Inc. (CAPR)

NMS – Real Time Price. Currency in USD

28.90

-1.05 (-3.51%)

At close: Mar 27, 2026, 4:00 PM EDT

29.39

+0.49 (1.70%)

After-hours: Mar 27, 2026, 5:15 PM EDT

About the company

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and exosome platform program consists of engineered exosomes for vaccine and therapeutic development and is in preclinical trial. In addition, it engages in developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases; It has license agreement with Johns Hopkins University, University of Rome License, and Cedars-Sinai Medical Center to develop and commercialize licensed products and licensed services under the licensed patent rights in all fields and a nonexclusive right to the know-how; Cell Line License Agreement with Life Technologies for the development of exosomes platform. The company was founded in 2005 and is headquartered in San Diego, California.

Key Executives

Name	Position
Catherine Lee Kelleher M.D.	Consultant
Dr. Frank Isaac Litvack FACC, M.D.	Executive Chairman of the Board
Dr. Kristi A. H. Elliott Ph.D.	Chief Operating & Science Officer
Dr. Linda Marbán Ph.D.	Co-Founder, President, CEO & Director
Dr. Micheal Binks M.D.	Chief Medical Officer
Mr. Anthony J. Bergmann M.B.A.	CFO & Corporate Treasurer
Mr. Mark Awadalla	Chief Development Officer